Novel drug GED-0301 for active Crohn's disease disappoints in phase III trial
08 Jun 2020
bởiStephen Padilla
The novel drug mongersen (GED-0301), an oral antisense oligodeoxynucleotide directed against Smad7, has failed to demonstrate efficacy against placebo in active Crohn’s disease (CD), according to the results of a phase III trial.